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The efficacy of cyclosporine (CsA; Sandimmune) in the prevention of allograft rejection in treatment of graft vs host and various autoimmune disorders is well documented (1, 2). Nevertheless the side effects of the drug, especially those on the kidney (3), have led investigators to search for other immunosuppressive drugs in which the frequency of the side effects is lessened. One such drug is cyclosporin G (CsG; , an analog of CsA in which the a-anunobutyric acid residue is replaced by norvaline in position 2 of the molecule (4, 5). Studies in animals suggest that CsG is as efficacious as CsA in the prevention of allograft rejection, with a similar or reduced frequency ofrenal side effects (4) (5) (6) (7) (8) (9) . A recent large-scale clinical trial5 in renal-transplant recipients also indicate that CsG has fewer renal side effects than CsA.
Although CsG is structurally similar to CsA, the pharmacokinetics of CsG and CsA differ inhumans (10, 11) . In a study investigating the pharmacokinetica of CsG in six patients with terminal renal failure, the volume of distribution and clearance of the drug were both greater than reported for CsA (10) . Differences in thedistribution of CsA and CsG in blood have also been reported, with the plasmalblood ratio for CsG in plasma separated at room temperature being 0. 8, compared with 0.6 reported for CsA (10) . This suggests that at equivalent whole-blood concentrations of the two drugs, more CsG than CsA would be found in the plasma. The structure and immunosuppressive activity of CsG metabolites have recently been published (12); however, no data on the distribution of these metabolites among blood components were reported.
We have previously reported in preliminary experiments that CsG exhibits a temperature-dependent distribution in blood, similar to that of CsA (13). However, no detailed study has been reported on the distribution of CsG among blood components. Such information is important in determining which medium would be most suitable for monitoring the concentrations of the drug in patients. We report here on the distribution of CsG among cellular components of whole blood, among plasma lipoprotein fractions, and on the free fraction of drug in plasma. We also discussthe implications of our findings for therapeutic monitoring of the drug.
MaterIals and Methods

Source of drugs and specimens.
CsG and [3H]CsG (60.2 Ci/mol) were obtained as gifts from Sandoz Inc.
(East Hanover, NJ). CsG metabolites GM1 and GM9 were isolated by HPLC in our laboratory from urine obtained from subjects receiving the drug, as previously described (12). The structure and purity ofthe metabolites were confirmed by fast atom bombardment mass spectroscopy and '3C nuclear magnetic resonance (12 expressed as the ratio of dpm found in the plasma fraction vs that in the erythrocyte fraction (plasma/RBC ratio) and the plasma fraction vs the total dpm added to whole blood (plasma/whole blood ratio).
Metabolite distribution.
Whole blood was supplemented with CsG metabolites GM1 and GM9 to the following concentrations:
100,500, 1000, and 5000 g/L. Specimens were equilibrated at 37 #{176}C for 30 mm, after which the cells were removed by centrifugation. The concentration of metabolites in the RBC and plasma fractions was determined by HPLC as previously de-. scribed (12) .
Determination of the free fraction. The free (unbound) fraction of CsG was determined by ultracentrifugation as describedby Legg and Rowland (14) . CsG was added to pooled human plasma to yield the following total concentrations: 50, 100, 250, 1000, 2500, and 5000 gfL. Tritiated CsG was added to yield 25 000 dpm/mL for all drug concentrations, except for the 50 and 100 jzg/L concentrations, for which the final count was 12 500 and 5000 dpm/mL, respectively. The plasma samples were placed in 13-mL polyallomer ultracentrifuge tubes (Beckman Inc., Palo Alto, CA) and gently cooled or heated to either 4 or 37 #{176}C. The tubes were placed in a T170 rotor and subjected to ultracentrifugation (Beckman L8-70M) for 15 h at 150 000 x g at the temperatures listed above. The centrifuge was allowed to stop without applying braking, to minimize turbulence. We obtained 21 0.5-mL aliquots from the top to the bottom of each tube. Each fraction was divided into portions, with one portion being used for protein determination and the remainder being used forcountingthe radioactivity. Fractions with a protein concentration <0.5 g/L were used to determine the amount of unbound CsG. The free fraction (%) was determined as the (total dpm in fractions containing <0.5 gIL protein)/total dpm added.
Binding to lpoproteins.
Lipoproteins were separated by ultracentrifugation as described by Redgrave et al. (15) . Briefly, the density of plasma was adjusted to 1.21 kg/L by adding KBr. The plasma was supplemented with CsG and [3HICsG as described in the preceding section. as described for the free fraction determinations. After centrif#{252}gation, the lipoprotein fractions-very-low-, low-, and high-density lipoproteins (VLDL, LDL, HDL)-and the plasma residuealbumin and other major plasma proteins-were collected. The identity of each fraction was confirmed by lipoprotein electrophoresis(16). The radioactivity of each fraction was counted as described above and reported as a percentage of total counts.
Binding to cellular components. Binding to cellular componentswas performed as previously described (15). To pooled fresh EDTA-treated whole blood was added [3H]CsG and CsG as described above for the free fraction determinations. Specimens were incubated at 37#{176}C for 30 mm, followed by dilution with an equal volume of isotonic saline that had been prewarmed to this temperature. The diluted blood [2.0 mL layered over 2.0 mL of Histopaque 1077 (Sigma Diagnostics, St. Louis, MO)] was centrifuged for30 mm at 1000 x g. The resulting plasma and lymphocyte layer were removed and set aside for counting the radioactivity. The RBC fraction (0.5 mL) was layered over 2.0 mL of Polymorphoprep (NycoredPharma, Torshov, Norway); after centrifugation for 30 mm at 1000 x g, the granulocyte and RBC layers were removed for counting the radioactivity. The purity of each cellular fraction, determined by flow cytometry, was >95%. The radioactivity in the plasma, lymphocyte, granulocyte, and RBC fraction was calculated as a percentage of the total counts of all four fractions.
Results
Temperature equilibration
studies. The plasma/whole blood and plasma/RBC ratio vs time of re-equilibration at 37#{176}C for whole blood having an initial temperature of 4#{176}C is shown in Figure 1 . The distribution of CaG did not change after 30 mm of re-equilibration. Identical results were found for blood having an initial temperature of 22#{176}C. We therefore chose a 30-mn re-equilibration time for all studies described below. After the re-equilibration, the plasmalwhole blood and plasma/ RBC ratios were relatively constant (-0.7-0.8) up to a CsG concentration of 1000 tg/L. At 5000 pg/L, this ratio increased to --1.0-1.1 for plasma/whole blood and up to 1.7 for plasma/RBC distribution. Distribution of metabolites. Table 1 summarizes the concentrations of the hydroxylated CsG metabolites GM1 and GM9, in whole blood, plasma, and RBC as well as their plasma/whole blood and plasma/RBC ratios. Both metabolites are sequestered in the erythrocytes to a greater extent than the parent drug is. The plasma/ whole blood and plasmalRBC ratios were relatively consistent for GM1 concentrations 1000 g/L, ranging from 0.42 to 0.52 and from 0.26 to 0.35, respectively; at 5000 p.g/L, both ratios increased to -1.0. In contrast, the effect of concentration of distribution of GM9 was more pronounced. At 100 .igfL, almost all the metabolite was sequestered within the erythrocytes, with the plasma/ whole blood and plasma/RBC ratio being 0.17 and 0.12, respectively. Both ratios proportionally increased with increasing metabolite concentration, reaching --0.90 at a concentration of 5000 p.g/L.
Free fraction.
After ultracentrifugation, 10 of the 0.5-inL aliquots from the centrifuge tubes were devoid of protein (i.e., protein <0.5 gIL). We used these aliquot.s to determine the free fraction of CsG. As Figure 2 shows, the majority of the drug is protein bound. Although CsG displayed no concentration-dependent protein binding, the proportion of the free fraction exhibited a temperature dependence. The free fraction at 37#{176}C (5-6%) was substantially lower than that at 4 #{176}C (13-17%).
Binding to cellular components.
The distribution of CsG in plasma, erythrocyte, lymphocyte, and granulecyte fractions is shown in Figure 3 . The binding to lymphocyte and granulocyte fractions was relatively constant, --6% and 2%, respectively, over the concentration range tested. In contrast, there was a proportional increase in the plasma fraction and a corresponding decrease in the erythrocyte fraction as the concentration Plasma/whole bloodratio 100 500 1000 5000 Plasma/RBC ratio 100 500 1000 5000 n = 6 each. (-10%); <10% of the total drug was found in the residual plasma fraction. As the concentration of the drug increased from 50 to 5000 pg/L, the proportion of drug bound to HDL tended to increase, with a corresponding decrease in the amount bound to LDL.
Discussion
In animal trials and in recent clinical trials, results indicate that CsG has similar immunosuppressive efficacy as CsA but exhibits fewer renal side effects (5_9)5 In the clinical studies, CsG concentrations were monitored in whole blood as a guide for dosage adjustment.5
The temperature-dependent distribution of CsG is similar to that of CsA; increasing temperature increases the concentration of these drugs in plasma. Re-equilibration is complete after 30 mm for blood having an initial temperature of either 4 or 22#{176}C. After this re-equilibration, the plasma/whole blood ratio for CsG (0.7-0.8) is greater than that for CsA, for which ratios of <0.6 have been reported (18-20) . These results are consistent with the previously reported distribution of CsG in blood from patients with chronic renal failure (10). Moreover, this indicates that at 37#{176}C more CsG than CsA is found in plasma. CsG also exhibits a concentration-dependent distribution, with more drug being found in the plasma phase at greater drug concentrations-siniilar to results reported for CsA (18) (19) (20) . This is most probably attributable to a saturation of erythrocyte binding sites for the drug.
The hydroxylated CsG metabolites GM1 and GM9 appear to be sequestered in the erythrocytes to a greater extent than the parent drug. Again, this is similar to previous findings for the corresponding CsA metabolites AM1 and AM9 (21,22) . Hydroxylated CsA metabolit.es are sequestered within erythrocytes, whereas the demethylated metabolit.es are found predominantly in the plasma fraction (22) ; whether this is also the case for CsG is not yet known, but the results reported here are consistent with this possibility. CsA metabolites AM1 and AM9 are present at concentrations close to or exceeding that of parent CsA (21,22) . Metabolite concentrations at steady-state must be determined to ascertain whether a similar situation exists for CsG. The use of whole blood instead of plasma as a matrix for CsG analysis will therefore include a relatively high concentration of metabolites, which may affect the measured concentrations of CsG, depending on the cross-reactivity or interference of such metabolites in the assay used.
The binding of CSG to cellular fractions within whole blood over the concentration range of 100-500 ,u.g/L is similar to that previously reported for CsA (15) : -6% is bound to lymphocytes, 2% to granulocytes, and 55% to erythrocytes. McKenna et al. (23) previously found the in vitro immunosuppressive potency of CsG to be slightly less than that of CsA and speculated that this might be due to decreased binding of the drug by lymphocytes. However, the data presented here do not support this hypothesis.
In plasma, CsG was primarily bound to lipoproteins, with 50% bound to HDL, 30% to VLDL, and 10% to LDL; the remaining amount was eitherunbound or associated with other plasma proteins-similar to what has previously been reported for CsA (24). However, because of the larger proportion of CsG found in the plasma fraction at 37#{176}C in comparison with CsA, we speculate that the lipoproteins have a greater capacity for binding CsG than CsA. An accurate determination of this would require measuring the absolute concentration of drug bound per milligram of lipid in each lipoprotein fraction, which we did not do in this study.
The therapeutic or toxic response to a drug is generally thought to be better related to its concentration in plasma water or free fraction than to its concentration in plasma or whole blood (25) . Measurement of the free fraction of hydrophobic drugs such as CsA or CsG has been problematic because of the drugs' binding to semipermeable membranes, which negates the use of such procedures as equilibrium dialysis and ultrafiltration. We therefore used an ultracentrifugation technique previously used for the determination of the free fraction of CsA (12). The magnitude of the free fraction of CsG was temperature dependent: at 37 and 4#{176}C, 5% and 15% ofthedrug, respectively, was found in the unbound fraction. The CsA free fraction was -5% at 37#{176}C (14, 17) . There was little variation in the CsG free fraction over the wide concentration range tested, which suggests that the lipoprotein fractions in plasma have an excessbinding capacity for the drug.
In general, the binding and distribution of CsG in whole blood resemble that previously reported for CsA, with the major difference being the larger proportion of CsG found in the plasma fraction. We therefore propose that the guidelines for monitoring CsA (26-28) will also apply for CsG. It is still premature to speculate on whether the therapeutic ranges for the two drugs are similar or different; data from clinical trials with CsG currently underway should clarifr this issue.
